全球腫瘤生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034）

腫瘤生物標記市場預計將從 2025 年的 441.7 億美元成長到 2034 年的 1,345 億美元，2026 年至 2034 年的複合年成長率為 13.17%。

隨著癌症診斷和治療越來越依賴精準醫療，全球腫瘤生物標記市場正在迅速擴張。腫瘤生物標記有助於癌症的早期發現、預測治療效果以及監測疾病進展。全球癌症發生率的上升以及對更精準診斷工具日益成長的需求，正在推動基於生物標記的檢測方法在臨床實踐和研究中的應用。

分子診斷、基因測序和蛋白質體學技術的進步是推動市場成長的關鍵因素。生物標記廣泛應用於標靶治療和臨床試驗，以識別合適的患者群體並改善治療效果。製藥公司也在生物標記研究領域投入大量資金，以支持創新癌症治療方法和個人化治療方案的開發。

展望未來，在持續的研究和技術創新推動下，腫瘤生物標記市場預計將保持強勁成長。液態生物檢體、伴隨診斷和人工智慧數據分析的日益普及將進一步加速生物標記的發現和應用。隨著醫療系統越來越重視癌症早期檢測和個人化治療策略，全球對腫瘤生物標記的需求將持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球腫瘤生物標記市場：按類型分類

• 市場分析、洞察與預測
• 乳癌
• 攝護腺癌
• 結腸癌
• 子宮頸癌
• 肝癌
• 肺癌
• 其他

第5章：全球腫瘤生物標記市場：依生物分子分類

• 市場分析、洞察與預測
• 基因生物標記
• 表觀遺傳生物標記
• 代謝生物標記
• 蛋白質體學生物標記
• 其他

第6章 全球腫瘤生物標記市場：依應用分類

• 市場分析、洞察與預測
• 藥物發現與開發
• 診斷
• 個人化醫療
• 其他

第7章 全球腫瘤生物標記市場：依技術分類

• 市場分析、洞察與預測
• 成像技術
• 體學

第8章 全球腫瘤生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abbott
  • Qiagen
  • Thermo Fisher Scientific Inc
  • Affymetrix Inc
  • Illumina Inc
  • Agilent Technologies
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc
  • Hologic Inc
  • Sino Biological Inc

The Oncology Biomarker Market size is expected to reach USD 134.50 Billion in 2034 from USD 44.17 Billion (2025) growing at a CAGR of 13.17% during 2026-2034.

The global oncology biomarker market is expanding rapidly as cancer diagnosis and treatment increasingly rely on precision medicine. Oncology biomarkers help detect cancer at an early stage, predict treatment responses, and monitor disease progression. Rising cancer incidence worldwide and the need for more accurate diagnostic tools are driving the adoption of biomarker-based testing in clinical practice and research.

Advancements in molecular diagnostics, genomic sequencing, and proteomics technologies are major factors accelerating market growth. Biomarkers are widely used in targeted therapies and clinical trials to identify suitable patient populations and improve treatment outcomes. Pharmaceutical companies are also investing heavily in biomarker research to support the development of innovative cancer therapies and personalized treatment approaches.

Looking ahead, the oncology biomarker market is expected to witness strong growth due to continuous research and technological innovation. The increasing use of liquid biopsy, companion diagnostics, and AI-driven data analysis will further enhance biomarker discovery and application. As healthcare systems emphasize early cancer detection and personalized treatment strategies, the demand for oncology biomarkers will continue to rise globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Others

By Biomolecule

• Genetic Biomarkers
• Epigenetic Biomarkers
• Metabolic Biomarkers
• Proteomic Biomarkers
• Others

By Application

• Drug Discovery and Development
• Diagnostics
• Personalized Medicine
• Others

By Technology

• Imaging Technology
• OMICS

COMPANIES PROFILED

• Abbott, Qiagen, Thermo Fisher Scientific Inc, Affymetrix Inc, Illumina Inc, Agilent Technologies, F HoffmannLa Roche AG, Merck Co Inc, Hologic Inc, Sino Biological Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONCOLOGY BIOMARKER MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONCOLOGY BIOMARKER MARKET: BY BIOMOLECULE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Biomolecule
• 5.2. Genetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Epigenetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Metabolic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Proteomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONCOLOGY BIOMARKER MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery and Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONCOLOGY BIOMARKER MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Technology
• 7.2. Imaging Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. OMICS Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONCOLOGY BIOMARKER MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Biomolecule
  • 8.2.3 By Application
  • 8.2.4 By Technology
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Biomolecule
  • 8.3.3 By Application
  • 8.3.4 By Technology
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Biomolecule
  • 8.4.3 By Application
  • 8.4.4 By Technology
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Biomolecule
  • 8.5.3 By Application
  • 8.5.4 By Technology
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Biomolecule
  • 8.6.3 By Application
  • 8.6.4 By Technology
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ONCOLOGY BIOMARKER INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott
  • 10.2.2 Qiagen
  • 10.2.3 Thermo Fisher Scientific Inc
  • 10.2.4 Affymetrix Inc
  • 10.2.5 Illumina Inc
  • 10.2.6 Agilent Technologies
  • 10.2.7 F. Hoffmann-La Roche AG
  • 10.2.8 Merck & Co. Inc
  • 10.2.9 Hologic Inc
  • 10.2.10 Sino Biological Inc